Clinical Trials Directory

Trials / Completed

CompletedNCT06337396

Omic Approaches to Neurodevelopmental Disabilities

Omic Approaches to Characterize the Functional and Phenotypic Consequences of Rare Structural Genomic Variants in Neurodevelopmental Disabilities and Congenital Anomalies

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
22 (actual)
Sponsor
IRCCS Eugenio Medea · Academic / Other
Sex
All
Age
4 Years – 18 Years
Healthy volunteers
Not accepted

Summary

to bridge the gap between the molecular structure of CNV and the effect on the phenotype, considering NDDs as complex diseases, as they are a consequence of the imbalance in several dosage-sensitive genes, we might try to approach them through different --omics investigations (genomics, epigenomics, transcriptomics) according to the emerging field of network medicine. This holistic can provide valuable insight into understanding peculiar molecular mechanisms and unsuspected molecular interactions that contribute to the pathogenesis of the condition and possibly pave the way for uncovering new drug strategies that even if they do not heal the patient may improve his performance and the social interaction

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTWGS and transcriptome analysisIn light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways

Timeline

Start date
2021-05-05
Primary completion
2023-07-28
Completion
2023-12-31
First posted
2024-03-29
Last updated
2024-03-29

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06337396. Inclusion in this directory is not an endorsement.